- Biocon Biologics has announced a settlement with Regeneron, allowing it to commercialise Yesafili™, a biosimilar to Eylea®, in the U.S.
- The product is expected to launch in the second…
Join the vibrant privacy-ensured Dzambhala community on
Want to give feedback on this story? Write to us at [email protected]